Molecular Mechanisms of Epilepsy-Causing Mutations in IKM channels: anti-epileptic effect of Lipophilic compounds.
IKM 通道引起癫痫的分子机制:亲脂性化合物的抗癫痫作用。
基本信息
- 批准号:10543145
- 负责人:
- 金额:$ 31.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-01-01 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAlternative TherapiesAntiepileptic AgentsBrainCRISPR/Cas technologyCessation of lifeCysteineDataDefectDependenceDevelopmentDiseaseDrug DesignEpilepsyFunctional disorderGene DeliveryGenesGoalsHomeostasisHumanInduced MutationInduced pluripotent stem cell derived neuronsInheritedIntellectual functioning disabilityInterventionIon ChannelLeadLengthLinkMaintenanceMapsMeasuresMolecularMovementMutagenesisMutateMutationNeuronsPathogenesisPatientsPersonsPolyunsaturated Fatty AcidsPotassium ChannelProteinsResearchSeizuresSiteTechnologyTestingVariantViralWorkXenopus oocyteearly onsetfunctional restorationgenetic variantgenome editingimprovedinduced pluripotent stem celllipophilicitymutantneuronal excitabilitypatch clamppi bondprogramsreduce symptomssensorstructural determinantsunnatural amino acidsvoltage
项目摘要
Abnormal neuronal activity in the brain leads to epileptic seizures that, when repeated or prolonged, can cause
neuronal damage resulting in delayed psychomotor development and intellectual disability. Most genetic
variants associated with epilepsy are in genes encoding ion channels, including potassium channels that
regulate neuronal excitability such as IKM channels. Inherited mutations in the IKM channel cause a wide
spectrum of early-onset epileptic disorders. The long-term goal of this research program is to understand the
mechanisms by which the wt IKM channel work, how epilepsy-causing mutations lead to dysfunction of IKM
channels and to design drugs that correct IKM dysfunction. The objective of this application is to determine how
epilepsy-inducing mutations in the IKM subunits KCNQ2 and KCNQ3 cause channel malfunction. Because
polyunsaturated fatty acids (PUFAs) have been shown to alleviate the symptoms of intractable epileptic
seizures, we will investigate the mechanisms by which these compounds reverse channel malfunction and
therefore improve neuronal function. The overarching hypothesis is that that epilepsy-causing mutations in
KCNQ channels affect voltage sensor movement and that PUFAs can restore normal voltage dependence of
voltage sensor movement in mutated KCNQ channels. The rationale for the proposed research is that
understanding the molecular basis by which different mutations in the IKM channel are linked to epilepsy will not
only help explain epilepsy pathogenesis but also provide clues for intervention strategies. Guided by
preliminary data, we will test our hypothesis by pursuing three specific aims: (1) determine the mechanisms by
which epilepsy-causing mutations affect IKM channels function. (2) determine how PUFAs affect voltage sensor
and gate movements of IKM channels bearing epilepsy-associated mutations and to identify which PUFA
variants restores channel function, and (3) determine whether PUFAs reduce hyperexcitability on neurons
bearing epilepsy-causing mutations in IKM channels. Under the first Aim, we will combine cysteine accessibility
and VCF approaches to simultaneously measure voltage sensor movement and gate opening in the wt IKM and
a set of epilepsy-associated mutants. This will allow us to determine how mutations affect the movement of the
voltage sensor and the activation gate in KCNQ2 and KCNQ3 channels. We will also incorporate unnatural
amino acids (UUAs) into mutated channels (UUAs mutagenesis) to further map the molecular determinants of
channel dysfunction. Under Aim 2, we will test PUFA variants with different chain lengths, different acyl chains
and different types of polar head groups to determine the molecular mechanism of PUFA’s effects on these
mutations. Under the third Aim, we will test PUFA variants that can correct channel function and restore activity
in iPSC-derived cortical neurons bearing epilepsy-associated mutations in KCNQ2 and/or KCNQ3. The
proposed research is significant because the anticipated results will provide the mechanistic basis for how
mutations cause IKM channel defects and will show proof-of-concept that PUFAs can act as antiepileptic drugs.
大脑中异常的神经元活动会导致癫痫发作,当反复或延长时,
神经元损伤导致延迟的精神发育和智力残疾。大多数遗传
与癫痫相关的变异存在于编码离子通道的基因中,包括钾通道,
调节神经元兴奋性,如IKM通道。IKM通道中的遗传突变导致广泛的
早发性癫痫疾病的范围。这项研究计划的长期目标是了解
野生型IKM通道的工作机制,癫痫突变如何导致IKM功能障碍
并设计纠正IKM功能障碍的药物。本申请的目的是确定如何
IKM亚基KCNQ 2和KCNQ 3中的癫痫诱导突变导致通道功能障碍。因为
多不饱和脂肪酸(PUFA)已被证明可以缓解顽固性癫痫的症状,
癫痫发作,我们将研究这些化合物逆转通道功能障碍的机制,
从而改善神经元功能。最重要的假设是,
KCNQ通道影响电压传感器运动,PUFA可以恢复正常的电压依赖性,
突变的KCNQ通道中的电压传感器移动。拟议研究的理由是,
了解IKM通道中不同突变与癫痫相关的分子基础,
不仅有助于解释癫痫发病机制,而且为干预策略提供线索。指导
初步的数据,我们将测试我们的假设,追求三个具体目标:(1)确定机制,
哪些致痫突变影响IKM通道功能。(2)确定PUFA如何影响电压传感器
以及携带癫痫相关突变的IKM通道的门控运动,并确定哪些PUFA
变体恢复通道功能,以及(3)确定PUFA是否降低神经元的过度兴奋性
在IKM通道中携带导致癫痫的突变。在第一个目标下,我们将结合联合收割机半胱氨酸可及性
和VCF方法,以同时测量wt IKM中的电压传感器移动和栅极开度,
一组癫痫相关的突变体这将使我们能够确定突变如何影响细胞的运动。
电压传感器和KCNQ 2和KCNQ 3通道中的激活门。我们还将结合非自然的
氨基酸(UUAs)突变的通道(UUAs诱变),以进一步映射的分子决定簇
通道功能障碍在目标2下,我们将测试具有不同链长、不同酰基链的PUFA变体,
和不同类型的极性头部基团,以确定PUFA对这些影响的分子机制,
突变。在第三个目标下,我们将测试可以纠正通道功能并恢复活性的PUFA变体
在iPSC衍生的皮质神经元中,KCNQ 2和/或KCNQ 3中携带癫痫相关突变。的
拟议的研究是重要的,因为预期的结果将提供机制的基础,
突变导致IKM通道缺陷,并将证明PUFA可以作为抗癫痫药物的概念。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rene Barro-Soria其他文献
Rene Barro-Soria的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rene Barro-Soria', 18)}}的其他基金
Molecular Mechanisms of Epilepsy-Causing Mutations in IKM channels: Anti-epileptic effect of Lipophilic compounds.
IKM 通道中癫痫引起突变的分子机制:亲脂性化合物的抗癫痫作用。
- 批准号:
10399187 - 财政年份:2021
- 资助金额:
$ 31.71万 - 项目类别:
Molecular Mechanisms of Epilepsy-Causing Mutations in IKM channels: anti-epileptic effect of Lipophilic compounds.
IKM 通道引起癫痫的分子机制:亲脂性化合物的抗癫痫作用。
- 批准号:
10318601 - 财政年份:2020
- 资助金额:
$ 31.71万 - 项目类别:
Molecular Mechanisms of Epilepsy-Causing Mutations in IKM channels: anti-epileptic effect of Lipophilic compounds.
IKM 通道引起癫痫的分子机制:亲脂性化合物的抗癫痫作用。
- 批准号:
10450391 - 财政年份:2020
- 资助金额:
$ 31.71万 - 项目类别:
Molecular Mechanisms of Epilepsy-Causing Mutations in IKM channels: anti-epileptic effect of Lipophilic compounds.
IKM 通道引起癫痫的分子机制:亲脂性化合物的抗癫痫作用。
- 批准号:
9885843 - 财政年份:2020
- 资助金额:
$ 31.71万 - 项目类别:
Polyunsaturated fatty acids as anti-arrhythmic agents.
多不饱和脂肪酸作为抗心律失常剂。
- 批准号:
10604252 - 财政年份:2016
- 资助金额:
$ 31.71万 - 项目类别:
相似海外基金
Development of education and dissemination methods for psychiatric nurses to introduce complementary and alternative therapies from the physical side
开发精神科护士的教育和传播方法,从身体方面引入补充和替代疗法
- 批准号:
26463484 - 财政年份:2014
- 资助金额:
$ 31.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Alternative therapies for antibiotic-resistant Helicobacter pylori infection
抗生素耐药性幽门螺杆菌感染的替代疗法
- 批准号:
23590890 - 财政年份:2011
- 资助金额:
$ 31.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Alternative Therapies for Benign Prostate Symptoms
良性前列腺症状的替代疗法
- 批准号:
8147503 - 财政年份:2010
- 资助金额:
$ 31.71万 - 项目类别:
Scientific evaluation of therapeutic effects and mechanism of alternative therapies using PET molecular imaging technique.
利用PET分子成像技术科学评估替代疗法的治疗效果和机制。
- 批准号:
21590754 - 财政年份:2009
- 资助金额:
$ 31.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Treating Burn injuries: First-aid and alternative therapies
治疗烧伤:急救和替代疗法
- 批准号:
nhmrc : 409902 - 财政年份:2006
- 资助金额:
$ 31.71万 - 项目类别:
NHMRC Postgraduate Scholarships
PREVENTING COGNITIVE DECLINE WITH ALTERNATIVE THERAPIES
通过替代疗法预防认知能力下降
- 批准号:
7206559 - 财政年份:2005
- 资助金额:
$ 31.71万 - 项目类别:
Alternative Therapies for Alcohol and Drug Abuse
酒精和药物滥用的替代疗法
- 批准号:
6861518 - 财政年份:2004
- 资助金额:
$ 31.71万 - 项目类别:
Alternative Therapies for Alcohol and Drug Abuse
酒精和药物滥用的替代疗法
- 批准号:
6952268 - 财政年份:2004
- 资助金额:
$ 31.71万 - 项目类别:
Alternative Therapies for Alcohol and Drug Abuse
酒精和药物滥用的替代疗法
- 批准号:
7115879 - 财政年份:2004
- 资助金额:
$ 31.71万 - 项目类别:
Alternative Therapies for Alcohol and Drug Abuse
酒精和药物滥用的替代疗法
- 批准号:
7237832 - 财政年份:2004
- 资助金额:
$ 31.71万 - 项目类别: